Management of Febrile Neutropenia in Cancer Patients

Patient Characteristics and Risk Factors

• A 67-year-old female with metastatic gallbladder cancer on dendritic cell therapy is at high risk for febrile neutropenia due to advanced age (>65 years), metastatic disease, and previous treatment with dendritic cell therapy 1
• The National Comprehensive Cancer Network recommends considering these risk factors when managing febrile neutropenia in cancer patients 1

Management Recommendations

• The National Comprehensive Cancer Network recommends adding G-CSF to the current regimen to address neutropenia in cancer patients on chemotherapy, particularly those with high-risk clinical features such as advanced age, metastatic disease, and poor performance status 1
• G-CSF is recommended for patients with high-risk clinical features, including advanced age (>65 years), metastatic disease, and poor performance status, to reduce the risk of febrile neutropenia 1

Monitoring and Optimization

• Daily complete blood count and monitoring for adverse effects of G-CSF (such as bone pain, headache, and fever) are recommended to assess response to G-CSF and optimize treatment 1